Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 11/20 | 0.57 |
| ▸ | INSR | P06213 | 10/20 | 0.57 |
| ▸ | IGF1R | P08069 | 10/20 | 0.57 |
| ▸ | EGFR | P00533 | 9/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | STK10 | O94804 | 1/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | CD74 | P04233 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | FES | P07332 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716547 | 0.86 | ALK (0.65) | ALKINSRIGF1REGFRLRRK2 | |
| SCHEMBL3715939 | 0.82 | EGFR (0.67) | ALKINSRIGF1REGFRLRRK2 | |
| SCHEMBL26090489 | 0.80 | INSR (0.75) | ALKINSRIGF1REGFRLRRK2 | |
| SCHEMBL30378071 | 0.80 | INSR (0.75) | ALKINSRIGF1REGFRLRRK2 | |
| SCHEMBL26089363 | 0.80 | INSR (0.77) | ALKINSRIGF1REGFRLRRK2 | |
| SCHEMBL26089299 | 0.78 | ALK (0.83) | ALKINSRIGF1REGFRLRRK2 | |
| SCHEMBL22027940 | 0.76 | EGFR (0.81) | ALKINSRIGF1REGFR | |
| SCHEMBL3714778 | 0.75 | ALK (0.66) | ALKINSRIGF1REGFRLRRK2 | |
| SCHEMBL18912630 | 0.75 | INSR (0.68) | ALKINSRIGF1REGFRLRRK2 | |
| SCHEMBL10232628 | 0.74 | INSR (0.59) | ALKINSRIGF1REGFRLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | claimed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | claimed |
| WO-2010138578-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| EP-2435422-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8486933-B2 | Pyrimidine inhibitors of kinase activity | ABBVIE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| WO-2010138578-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305112-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | IGF1R, TK1, CDK2 | ALK 397/4885INSR 6/4885IGF1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.